Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


National Drug Schedules: Final Recommendations for esomeprazole 20 mg

The interim recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) on October 11, 2018 that:

  • esomeprazole or its salts, when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole, be granted Schedule III status
  • esomeprazole or its salts, EXCEPT when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg in package sizes of no more than 280 mg of esomeprazole, be retained in Schedule I;

were finalized effective November 12, 2018. Final approval of the interim recommendations was made by NAPRA’s Board of Directors. In this case, NAPRA did not receive any comments during the 30-day review period. The National Drug Schedules will be revised accordingly.

 

Date: